Galera Therapeutics, Inc. (GRTX) Share-based Payment Arrangement, Expense USD 2018 - 2024

Historical data

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: Galera Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2024.
Galera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $875 K, a 40% decline year-over-year.
Galera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $4.98 M, a 26.5% decline year-over-year.
Galera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5.56 M, a 22.4% decline from 2022.
Galera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7.16 M, a 0.93% decline from 2021.
Galera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7.23 M, a 30.6% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q1 2024	$4.98 M	$875 K	-$583 K	-40%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-13
Q4 2023	$5.56 M	$1.19 M	-$549 K	-31.6%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-28
Q3 2023	$6.11 M	$1.39 M	-$360 K	-20.6%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-14
Q2 2023	$6.47 M	$1.53 M	-$305 K	-16.7%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-14
Q1 2023	$6.77 M	$1.46 M	-$390 K	-21.1%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-13
Q4 2022	$7.16 M	$1.74 M	-$223 K	-11.4%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-28
Q3 2022	$7.39 M	$1.75 M	-$120 K	-6.42%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-14
Q2 2022	$7.51 M	$1.83 M	+$219 K	+13.6%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-14
Q1 2022	$7.29 M	$1.85 M	+$57 K	+3.18%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q4 2021	$7.23 M	$1.96 M	+$591 K	+43.2%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-08
Q3 2021	$6.64 M	$1.87 M	+$365 K	+24.3%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-09
Q2 2021	$6.28 M	$1.61 M	+$158 K	+10.9%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	$6.12 M	$1.79 M	+$581 K	+48%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-16
Q4 2020	$5.54 M	$1.37 M	+$562 K	+69.7%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-10
Q3 2020	$4.97 M	$1.51 M	+$985 K	+189%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-10
Q2 2020	$3.99 M	$1.45 M	+$888 K	+157%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-10
Q1 2020	$3.1 M	$1.21 M	+$711 K	+142%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q4 2019	$2.39 M	$806 K			Oct 1, 2019	Dec 31, 2019	10-K	2021-03-11
Q3 2019		$520 K	+$300 K	+136%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-10
Q2 2019		$565 K			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-10
Q1 2019		$499 K			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12
Q3 2018		$220 K			Jul 1, 2018	Sep 30, 2018	10-Q	2019-12-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.